Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 14.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 14.0 Contact Hours.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Akcea Therapeutics; Alder BioPharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc.; Eisai; Jazz Pharmaceuticals, Inc.; Lilly; Mallinckrodt Pharmaceuticals; Mitsubishi Tanabe Pharma America, Inc.; Portola Pharmaceuticals, Inc.; Sarepta Therapeutics, Inc.; SK Life Science, Inc.; and Supernus Pharmaceuticals.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
1st Annual International Congress on the Future of Neurology™
1st Annual International Congress on the Future of Neurology™ — Call for Poster Abstracts!
The program chair of the 1st Annual International Congress on the Future of Neurology™ invites you to submit your abstracts to this year's Congress, to be held September 27-28, 2019, at the InterContinental New York Times Square in New York City.
Deadline for submission is
August 25, at 11:59 PM EST EXTENDED TO September 2, at 11:59 PM EST.
All poster abstract submissions must be made electronically through the Congress online abstract submission system.
Your abstract should be a short description of your work and contain all the elements necessary to define your goals and results to the reader. Authors will be required to disclose all financial relationships through the online system, to ensure quality and unbiased presentations. The formal poster session is not designated for credit.
Share your research or best practices with your peers. Categories of submission include the following:
- Alzheimer Dementia
- Stroke Care
- Neuromuscular Disease
- Sleep Disorders
- Multiple Sclerosis
- Movement Disorders
- Migraine Therapy
- Other, Including Preclinical Studies
The program chairs will evaluate the scientific quality of the submitted abstracts on the basis of the following criteria: novelty of the research, significance of the findings, and clarity. Incomplete abstracts will not be reviewed. Please note that we will consider case series of more than 5 reports, but we are not accepting case series of <5 patients and single-patient case reports.
Notification of acceptance or regret will be delivered via email to the presenter(s) of each poster abstract by September 16, 2019. Please note that an author is required to be present during the poster session.
If selected for oral presentation, the presenting author will be given 10-15 minutes to present their abstract and 5 minutes for discussion and exchange with the audience, moderated by the chair. Oral presentations are scheduled for Friday afternoon, September 27, in the general session room. Please note, oral presentations can only be given by healthcare providers who are not employed by a for-profit organization, including biotech, financial, and pharmaceutical.
If accepted for presentation, abstracts and posters will be available for viewing online on the 1st Annual International Congress on the Future of Neurology™ website during and after the conference. The posters will be displayed for the length of the conference. The presentation at the 1st Annual International Congress on the Future of Neurology™ should reflect the submitted abstract, abstract title, authorship, and content.
All presenters must register to attend the 1st Annual International Congress on the Future of Neurology™. Please click here to register.
- Complete the abstract template provided on the 1st Annual International Congress on the Future of Neurology™ website.
- Limit is 2500 characters (abstract body, including spaces and 1 table).
Components of the Abstract Body Limit: 2500 Characters (1 table allowed)
Abstracts of Clinical Trials With Results to Be Presented
- Background/Significance – What was the problem, and why was it important? What knowledge are you building on? What was the intent or goal of the study? What did you want to learn?
- Materials and Methods – What was the trial design? What was the sample? What instruments were used? How was data collected and analyzed?
- Results – What were the findings?
- Conclusions – What do the findings mean?
Abstracts of Clinical Trials in Progress (ie, results not yet available)
- Background/Significance: What is the problem, and why is it important? What knowledge are you building on? What are the objectives of the study? What do you want to learn?
- Design and Methods: What is the trial design? What is the study population (including inclusion and exclusion criteria)? What is the statistical design? What are the study end points?
- Status: What is the current status of the trial (eg, enrollment status, participating study centers, anticipated completion date)?
Please submit any questions pertaining to abstract submissions to email@example.com using the subject line “IFN Abstract QUESTION.”
Author Consent and Waiver of Claims
Each Abstract Author agrees and certifies that he or she:
- Waives any and all claims against Physicians’ Education Resource®, LLC, sponsor of the 1st Annual International Congress on the Future of Neurology™, and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.
Note: The hotel is expected to sell out, and it is likely to do so before the discounted cutoff date of September 4, 2019. Reservations may be made online here.
Answers to Frequently Asked Questions
Abstracts in the following categories will also be considered for presentation:
- Basic science (preclinical research), pharmacokinetics/pharmacodynamics, and health economic outcomes research
- Case series of ≥5 patients (case series of <5 patients and single-patient case reports are not accepted)
- Encore presentations (abstract and poster must indicate where originally presented)
- Late-breaking abstracts
- Literature reviews
- Research abstracts funded by for-profit organizations, including biotech and pharmaceutical
Trials in progress:
- Trial must be open to accrual
- Abstracts/posters for the “Trials in Progress” category cannot include end point data from the trial. If end point data are to be presented, please submit under the “Abstracts of Clinical Trials With Results to Be Presented” category.
- Abstracts are currently accepted only for poster presentation, not oral presentation
- Abstracts are not published, but are posted to the attendee eSyllabus
- Pharmaceutical industry authors are allowed to present abstracts
- A non-named author can present a poster if written permission to do so is provided by the lead author